Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients With Soft Tissue Sarcoma

NCT05836571 is registered in ClinicalTrials.gov with National Cancer Institute LAO as lead sponsor.

NCT NCT05836571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05836571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients With Soft Tissue Sarcoma
Lead sponsor
National Cancer Institute LAO
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 25, 2023
Completion date
May 15, 2028
Enrollment
66 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced extraskeletal myxoid chondrosarcoma, locally advanced leiomyosarcoma, locally advanced liposarcoma, locally advanced undifferentiated pleomorphic sarcoma, locally advanced unresectable soft tissue sarcoma, metastatic soft tissue sarcoma, metastatic undifferentiated pleomorphic sarcoma, unresectable leiomyosarcoma, unresectable liposarcoma, unresectable undifferentiated pleomorphic sarcoma